Clinical Trial Update: Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated the security of reducing ritonavir dose in HIV-infected patients treated with tipranavir/ritonavir 500/200 mg every 12 hours.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• tipranavir/ritonavir (tipranavir/ritonavir)

Snippet

Sponsor: Germans Trias i Pujol Hospital | Conditions: HIV Infections | Phase 4 | Status: COMPLETED